Canaccord maintains $3 target on Lucid Diagnostics stock

Published 24/03/2025, 20:22
Canaccord maintains $3 target on Lucid Diagnostics stock

On Monday, Canaccord Genuity maintained a Buy rating for Lucid (NASDAQ:LCID) Diagnostics Inc (NASDAQ:LUCD) with a steady price target of $3.00. The stock, which has surged nearly 97% over the past six months and trades near its 52-week high of $1.63, currently appears overvalued according to InvestingPro Fair Value metrics. Following the company’s fourth-quarter revenue report for the fiscal year 2024, which was slightly below expectations, Canaccord Genuity analyst Kyle Mikson reaffirmed the firm’s outlook. Despite a quarter-over-quarter decrease in the EsoGuard effective average selling price (ASP), Lucid Diagnostics saw a significant rise in processed test volume compared to the previous quarter, partly due to large-volume testing events.

Lucid Diagnostics recently announced several new reimbursement coverage policies for its EsoGuard test, alongside notable progress in the direct contracting channel. The company’s management anticipates a material expansion in revenue, supported by these developments. Moreover, there is an expectation for a draft update to the foundational local coverage determination (LCD) covering EsoGuard to be announced by MolDX in the first half of 2025, with a final updated LCD to follow in the subsequent months.

The analyst highlighted the company’s potential for increased adoption levels over time and the anticipated coverage for the EsoGuard test under the foundational LCD, considering these factors as positive indicators for the stock’s future performance. Canaccord Genuity’s stance reflects confidence in Lucid Diagnostics’ growth trajectory and market position.

In other recent news, Lucid Diagnostics Inc. reported a substantial 84% year-over-year increase in the volume of its EsoGuard tests for the fourth quarter of 2024, reaching 4,042 tests. Despite this growth, the company did not meet consensus revenue expectations, reporting $1.19 million in revenue, falling short of the $1.43 million forecast. The earnings per share (EPS) also missed expectations, with a reported -$0.19 compared to the anticipated -$0.17. Needham analysts responded to these developments by raising the price target for Lucid Diagnostics to $3.00 from $2.50, maintaining a Buy rating, citing optimism about future revenue growth. The company ended the quarter with approximately $37 million in pro forma cash, supported by a $15 million capital raise in March. Lucid Diagnostics also secured a significant NIH grant to expand its cancer screening indications, and the company is looking forward to a potential Medicare coverage decision in the first half of 2025. Analysts at Needham project that the gap between revenue and EsoGuard test volume growth will narrow, driven by anticipated increased insurance coverage.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.